Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6968482 | 0.87 | TDP1 (0.48) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL4189484 | 0.86 | MAPT (0.45) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL4168700 | 0.86 | GAA (0.41) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL6981517 | 0.78 | L3MBTL1 (0.44) | MAPTL3MBTL1EGLN1 | |
| SCHEMBL3886045 | 0.76 | AKR1C3 (0.47) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL14567550 | 0.75 | MAP4K4 (0.39) | TDP1MAPTNQO2SMN1; SMN2 | |
| SCHEMBL3890768 | 0.75 | CYSLTR2 (0.44) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL29711483 | 0.75 | CYSLTR2 (0.44) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL1957784 | 0.75 | CYSLTR2 (0.44) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL10838810 | 0.74 | CYP1A2 (0.43) | CYP1A2GAACYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183379-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | claimed |
| US-20090069372-A1 | ANTITUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | claimed |
| US-7470788-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2008-12-30 | — | — | US | claimed |
| EP-1940794-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007030780-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2007-03-15 | — | — | WO | claimed |
| US-20070060612-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-15 | — | — | US | claimed |
| US-20070054938-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-08 | — | — | US | claimed |
| US-8183379-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183379-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090069372-A1 | ANTITUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-20090069372-A1 | ANTITUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-7470788-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470788-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1940794-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007030780-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070060612-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-15 | — | — | US | disclosed |
| US-20070060612-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-15 | — | — | US | disclosed |
| US-20070054938-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-08 | — | — | US | disclosed |
| US-20070054938-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060612-A1 | Antitumor agents | TP53, NHERF1, MCL1 | CYP1A2 3812/4885GAA 1431/4885CYP2C9 3570/4885 |
| US-20090069372-A1 | ANTITUMOR AGENTS | NHERF1, BACH1, MCL1 | CYP1A2 4137/4885GAA 1461/4885CYP2C9 3860/4885 |
| US-20070054938-A1 | Antitumor agents | TP53, NHERF1, MCL1 | CYP1A2 3812/4885GAA 1431/4885CYP2C9 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.